Want to see CRVO full AI Analyst Report?
CRVO Stock Chart & Stats
$2.66
>-$0.01(-0.37%)
At close: 4:00 PM EDT
$2.66
>-$0.01(-0.37%)
Day’s Range― - ―
52-Week Range$2.13 - $11.25
Previous CloseN/A
Volume118.08K
Average Volume (3M)112.80K
Market Cap
$34.90M
Enterprise Value$27.33M
Total Cash (Recent Filing)$12.92M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Aug 17, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.27
Shares Outstanding13,526,233
10 Day Avg. Volume143,994
30 Day Avg. Volume112,798
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)0.00
P/FCF Ratio-3.05
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue84.74
Enterprise Value/Gross Profit84.74
Enterprise Value/Ebitda-0.91
Forecast
1Y Price Target
$20.40Price Target Upside666.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.69
Revenue Forecast (FY)$228.57K
Bulls Say, Bears Say
Bulls Say
Clinical Data Alignment & Phase 3 StrategyRobust dose-exposure and biomarker analyses clarified why prior results varied and identified a trough threshold tied to benefit. Regulatory alignment on a Phase 3 plan reduces execution risk, enabling a focused pivotal design that increases the chance of a definitive outcome and partner interest over the next 2–6 months.
Strengthened Intellectual PropertyA granted U.S. patent for neflamapimod in DLB patients without major Alzheimer co-pathology materially extends exclusivity. This raises barriers to entry, enhances licensing and partnership leverage, and supports longer-term commercial optionality if clinical efficacy is confirmed.
Low Financial LeverageZero reported debt reduces near-term refinancing and interest risks, giving management flexibility to prioritize R&D and negotiate non-debt funding. For a clinical-stage biopharma, low leverage preserves strategic optionality during multi-stage development and partner discussions.
Bears Say
Severe Cash BurnPersistent, large negative operating cash flow signifies material cash burn relative to current resources. Continued outsized R&D and G&A spend without product revenue makes program continuity dependent on new financing, increasing execution risk and potential disruption to multi-indication development plans.
Minimal And Declining RevenueRevenue collapsed after grant exhaustion, reflecting no commercial products and limited non-dilutive funding. The lack of recurring revenue leaves the company reliant on capital markets for operations, reducing internal funding flexibility and increasing vulnerability if financing windows tighten.
Eroding Balance Sheet And Limited RunwayMaterial equity erosion and a modest cash balance constrain the firm's ability to sustain multiple clinical programs. With runway reported into Q3 2026, near-term financing becomes critical; failure to secure favorable funding would force program prioritization or accelerate dilutive financings, affecting long-term execution.
CervoMed News
CRVO FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was $2.13 and its highest was $11.25 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is $34.90M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is Aug 17, 2026 which is in 14 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on May 18, 2026. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.786 by -$0.074.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate is -0.8.
How many shares outstanding does CervoMed have?
CervoMed has 13,526,233 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.786. Following the earnings report the stock price went down -11.628%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in CRVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CervoMed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.40 (666.92% Upside)
$20.40 (666.92% Upside)
Hedge Fund Trend
Decreased
By 74.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-49.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-60.82%
Trailing 12-Months
Company Description
CervoMed
CervoMed, Inc. (CRVO) is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system (CNS) and neurodegenerative diseases. The company’s activities center on research and clinical development of drug candidates (including neflamapimod) intended to address conditions such as dementia-related disorders. As a development-stage biopharma company, it does not provide commercial healthcare services and is primarily engaged in advancing its pipeline through clinical trials and regulatory pathways.
CRVO Stock 12 Month Forecast
Average Price Target
$20.40
▲(666.92% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Jasper Therapeutics
―
Prelude Therapeutics
―
Estrella Immunopharma
―
Ownership Overview
37.22% Insiders
2.74% Mutual Funds
0.61% Other Institutional Investors
56.89% Public Companies and
Individual Investors